Increased Technology Use Associated With Lower A1C in a Large Pediatric Clinical Population.

Alonso, G Todd; Triolo, Taylor M; Akturk, Halis Kaan; Pauley, Meghan E; Sobczak, Marisa; Forlenza, Gregory P; Sakamoto, Casey; Pyle, Laura et al. · Diabetes Care · 2023

retrospective_cohort · Level III

Where this comes from

Abstract

While continuous glucose monitors (CGMs), insulin pumps, and hybrid closed-loop (HCL) systems each improve glycemic control in type 1 diabetes, it is unclear how the use of these technologies impacts real-world pediatric care. We found 1,455 patients aged <22 years, with type 1 diabetes duration >3 months, and who had data from a single center in between both 2016-2017 (n = 2,827) and 2020-2021 (n = 2,731). Patients were grouped by multiple daily injections or insulin pump, with or without an HCL system, and using a blood glucose monitor or CGM. Glycemic control was compared using linear mixed-effects models adjusting for age, diabetes duration, and race/ethnicity. CGM use increased from 32.9 to 75.3%, and HCL use increased from 0.3 to 27.9%. Overall A1C decreased from 8.9 to 8.6% (P < 0.0001). Adoption of CGM and HCL was associated with decreased A1C, suggesting promotion of these technologies may yield glycemic benefits.

Medical subject headings